The Life Sciences, Public Companies and Mergers + Acquisitions teams advised Neon Therapeutics (Nasdaq: NTGN) on its acquisition by BioNTech (Nasdaq: BNTX), which closed today in an all-stock transaction valued at $97 million.
The new subsidiary based in Cambridge, Massachusetts, will operate under the name of BioNTech US Inc. and serve as BioNTech’s U.S. headquarters. BioNTech is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The merger agreement was first announced on January 16, 2020.
The Goodwin team was led by partners Mitch Bloom, Jim Matarese, Art McGivern, and Lillian Kim, and associates Tobias Schad, Will Stanton, and Kristen Kennedy, with assistance from partners and counsel Janet Andolina, Kyle Pine, Sarah Bock, Jennifer Fay, Deb Birnbach, Jesse Nevarez, Andrea Agathoklis, Kara Kuritz, Jake Osborn, Stephanie Philbin, Roger Cohen, Ce Li, and Jackie Klosek, and associates Gabriela Morales, Morgan Frisoli, Caroline Galiatsos and William Evans.